Fig. 4From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysisCluster analysis of the first part of the network analysis according to the SUCRA score. Abbreviations: Apa: apatorsen; Icr: icrucumab; Paz: pazopanib; Ram: ramucirumab; Tax: taxaneBack to article page